0EVI Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Innate Pharma SA

Watchlist Manager

Watchlist

Price: 1.632 EUR 3.23% Market Closed

Market Cap: €132.1m

	Innate Pharma SA LSE:0EVI	FR
	Grab Holdings Ltd NASDAQ:GRAB	SG
A	Air Products and Chemicals Inc XMUN:AP3	US

Profitability Summary

Innate Pharma SA's profitability score is 25/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Strong 3Y Average Gross Margin

67%

Declining Gross Margin

93% > 1%

Negative Operating Margin

-1.834%

Negative 3Y Average Operating Margin

-570%

Declining Operating Margin

-152% > -1.834%

Negative Net Margin

-1.765%

Negative 3Y Average Net Margin

-537%

Declining Net Margin

-144% > -1.765%

Negative Free Cash Flow Margin

-1.898%

Negative 3Y Average Free Cash Flow Margin

-478%

Declining Free Cash Flow Margin

-74% > -1.898%

Exceptional ROE

764%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-221%

Declining ROIC

-55% > -835%

View All

Hide

Collapse

25 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.